The Food and Drug Administration (FDA) granted approval for niraparib for some women with advanced ovarian cancer.

Niraparib is one of a class of drugs known as PARP inhibitors, which work by disrupting cancer cells’ ability to repair DNA damage, which ultimately means that cancer cells will be more likely to die. The approval makes niraparib the third PARP inhibitor approved by the FDA for treating ovarian cancer. 

Niraparib is taken as a pill. They work for women who have had a recurrence of advanced ovarian, fallopian tube, or primary peritoneal cancer.

If this treatment option seems right for you, learn more here, or ask your doctor for more information.